NUTX

On the surface NUTX looks like a fundamental dream: FY2025 revenue of $875M (+82.4% YoY), operating income of $276M (31.5% margin), operating cash flow of $248M (+971.7%), cash of $186M, and stockholders' equity nearly 2.5x'd to $329M. At $146.95 the stock trades at just 14x diluted EPS of $10.48 and 1.2x sales — optically cheap for a business throwing off these margins. ROE of 21.5% and a current ratio of ~3.4x (current assets $539M vs current liabilities $158M) round out a balance sheet that, in isolation, screams quality at a discount.

The 10-K filing language detonates that read. A consolidated securities class action (In re Nutex Health Inc. Securities Litigation, S.D. Tex. 4:25-cv-03999) covering Feb 5 – Aug 14, 2025 alleges that management made material misstatements about (a) the conduct of a third-party vendor pursuing claims under the No Surprises Act IDR process and (b) internal controls over financial reporting and the accounting treatment of non-cash stock-based compensation. Two derivative actions have been consolidated on the same operative facts. Nutex operates 'as an out-of-network provider' and 'does not have negotiated reimbursement rates with insurance companies,' with 97% of revenue from insurance — meaning the IDR/No Surprises Act mechanism the plaintiffs are attacking is the actual engine behind the 2024→2025 revenue doubling. If even a portion of that IDR revenue is restated or future collections normalize, the FY2025 P&L is unreliable as a run-rate.